Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.
A new generation of "bivalent" gp120-based vaccines, effective against subtype B and subtype E viruses, has been developed. Antisera from rabbits and humans immunized with these vaccines are able to neutralize macrophage tropic and T-cell tropic viruses grown in activated peripheral blood mononuclear cells (PBMCs). These vaccines are now available for efficacy trials to determine the role of humoral immunity in providing protection against human immunodeficiency virus type 1 (HIV-1) infection.
Berman
P W
PW
VaxGen, Inc., South San Francisco, California 94080, USA. pwb@gene.co
D016915:AIDS Vaccines; D000595:Amino Acid Sequence; D000818:Animals; D014644:Genetic Variation; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000276:immunology*; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology; D006801:Humans; D008264:Macrophages / Q000276:immunology; D017720:Molecular Epidemiology; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011817:Rabbits; D013601:T-Lymphocytes / Q000276:immunology
D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120